Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-DOPA II - PET Imaging Optimization
NCT04706910Phase 3Recruiting
- Sponsor
- University of Alberta
- Start
- Jan 2021
- Primary completion
- Dec 2027
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
A Phase 3 trial of Fluorodopa F 18 in congenital hyperinsulinism (HI), neuroblastoma, Neuroendocrine Neoplasm (NEN), Parkinson's disease (PD), Lewy body dementia (LBD), sponsored by University of Alberta. Started Jan 2021; status: recruiting.
02
Drugs
Fluorodopa F 18
03
Conditions
congenital hyperinsulinism (HI)neuroblastomaNeuroendocrine Neoplasm (NEN)Parkinson's disease (PD)Lewy body dementia (LBD)
Beyond the preview
Go deeper on NCT04706910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04706910.